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Patients with bronchiectasis and chronic infection with Pseudomonas aeruginosa have more frequent 
pulmonary exacerbations and hospital admissions, reduced quality of life and survival, in comparison to 
those who are P. aeruginosa free [1]. Guidelines published by the British Thoracic Society recommend 
treatment to eradicate P. aeruginosa when first isolated in respiratory tract samples of people with 
bronchiectasis [2]. However, the best regimen to achieve eradication and how successful eradication is 
determined are not known.  
At the Northern Ireland Regional Respiratory Centre (Belfast, United Kingdom), the preferred eradication 
regimen is a combination of oral ciprofloxacin (for 6 weeks), and nebulised colistimethate sodium (for 3 
months)[3]. However, this regimen is varied, according to patient experience (e.g. drug allergy and/or 
intolerance), clinician judgement and the antimicrobial susceptibility profile of the P. aeruginosa isolate. 
Therefore, the aims of this study were to determine if the eradication regimens used differed in their 
efficacy, in order to optimise and standardise clinical practice.  
Adult patients with bronchiectasis who underwent treatment aimed at P. aeruginosa eradication 
between 1 January 2007 and 31 December 2014 were identified from the clinical database. Historical 
data were collected from medical notes. P. aeruginosa eradication was considered successful if all (and 
at least 3) bacteriologic cultures from respiratory samples collected during the 6-month period following 
the eradication attempt were negative for P. aeruginosa. Patients who remained on chronic (>3 months) 
nebulised antibiotics were excluded from the analysis, as this treatment could suppress bacterial growth 
and overestimate eradication success rate. . In order to select patients with recent acquisition of P. 
aeruginosa, we included only those who had never grown P. aeruginosa or those who were free of this 
bacteria for at least 2 years (and documented by 5 or more negative samples) before the eradication 
trial. All patients had a second confirmatory sample collected prior to initiation of eradication therapy.  
Sixty-four (64) patients who had at least one eradication attempt were identified. Their mean (SD) age 
was 64 (1.6) years, 58% (n=37) were male, and 63% (n=39/62) of patients were receiving azithromycin 
500 mg thrice weekly. Forced expiratory volume in one second (FEV1) was 1.70 (0.15) litres and Forced 
vital capacity 2.89 (0.19) litres. 
Eighty-four percent of patients (n=54) received an eradication regimen that included nebulised 
colistimethate sodium (table 1). The most frequent regimen used was the combination of nebulised 
colistimethate sodium with oral ciprofloxacin, prescribed for at least 3 weeks (n=27, 42%).  
Overall, the eradication success rate at 6 months was 52% (n=33) and 70% (n=23) of these patients 
remained P. aeruginosa free for at least 1 year. Treatment combinations including nebulised 
colistimethate sodium were more effective (n=31/54, 57%) than those with systemic antibiotics alone 
(n=2/10, 20%) (Student t-test, p=0.04).  
Intravenous anti-pseudomonal antibiotics (n=9/18, 50%) were not superior to oral ciprofloxacin 
(n=21/35, 60%) in the subgroup of patients who also received nebulised antibiotics as part of their 
regimen (table 1). Additionally, prolonged courses of oral ciprofloxacin (> 3 weeks) were no more 
efficient than shorter treatment periods (n=15/27, 56% vs n=6/8, 75%).  
The study population was stratified according to eradication outcome (success versus failure). 
Demographic and clinical data of both groups were compared in order to identify factors that could have 
impacted eradication outcome.  Age, gender, lung function and duration of infection prior to eradication 
were similar between groups. However, chronic azithromycin use was more frequent amongst patients 
who successfully cleared P. aeruginosa infection (75% vs 47%, p=0.04).   
This study suggests that eradication regimens combining nebulised and systemic antibiotics are more 
efficient for P. aeruginosa eradication than treatment without inhaled antibiotic. This finding supports 
results recently published by Orriols et al. [4]. In that study, the authors randomised 35 patients who 
recently acquired P. aeruginosa infection to receive 2 weeks of intravenous antibiotics (ceftazidime and 
tobramycin), followed by either 3 months of nebulised tobramycin or placebo. They found that the 
interval for recurrence of P. aeruginosa infection was extended in the tobramycin group and that the 
treatment arm had a reduced number of exacerbations and hospitalisations during the follow-up period. 
However, one third of patients in the tobramycin group experienced bronchospasm. In our cohort, 
respiratory symptoms associated with nebulised colistimethate sodium were infrequent as only 2 
patients had to discontinue the inhaled treatment prematurely. Although consistent with our findings, 
results from Orriols’ study must be interpreted cautiously due to the small sample size and limitations in 
study design and reporting.   
The potential benefit conferred by azithromycin on P. aeruginosa eradication needs further 
investigation. Azithromycin may contribute to biofilm disruption, and may augment  the action of anti-
pseudomonal antibiotics [5-7] . 
In conclusion, this study suggests the superiority of a combination of systemic (oral or intravenous) and 
inhaled antibiotics in the initial eradication treatment of P. aeruginosa infection in bronchiectasis 
patients, in comparison to systemic antibiotics only. Considering the literature gap addressing 
P. aeruginosa eradication in this population, these findings should  inform the design of appropriate 
randomised clinical trials, to determine the best therapeutic approach, including the role of macrolides, 
in the treatment of new infections with P. aeruginosa in people with bronchiectasis.  
  
 
Table 1: Frequency and efficacy of antibiotics used as first-line eradication regimens.   
Treatment 
Nebulised colistimethate sodium (3 months) & No nebulised colistimethate sodium 
Cipro 
(≤3 weeks) 
Cipro 
(>3 weeks) 
IVs 
(2weeks) 
Cipro + 
IVs 
Nil 
else Cipro IVs Cipro + IVs 
Patients, 
n  8 27 13 5 1 6 2 2 
Success,  
n (%) 6 (75) 15 (55.5) 7 (54) 2 (40) 
1 
(100) 1 (17) 0 (0) 1 (50) 
Total 31/54 (57%) 2/10 (20%) 
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